(AS2) Treatment of Recurrent Glioblastoma with Oscillating Magnetic Fields Using a Comfortable Helmet-bench to Bedside Studies Including Striking Results in Three End Stage Patients
Vice Chairman and Residency Program Director, Director, Kenneth R. Peak Brain and Pituitary Tumor Treatment Center Houston Methodist Hospital Houston, Texas, United States
Disclosure(s):
David S. Baskin, MD, FACS, FAANS: No financial relationships to disclose
Introduction: We have developed a noninvasive spinning oscillating magnetic field-generating device (Oncomagnetic Device) that causes a reduction in the contrast-enhance tumor (CET) volume of recurrent glioblastoma (GBM). The cellular mechanism of action of this device is distinct from that thought to be involved with Optune tumor-treating field treatment, and comprises the disruption mitochondrial electron transport, leading to a selective cytotoxic elevation of reactive oxygen species only in cancer cells. After performing pre-clinical studies, we assessed the response to noninvasive Oncomagnetic therapy (OMT) in three end-stage recurrent GBM patients.
Methods: We provided OMT to a 55-year-old man (DR), a 79-year-old woman (LZ) and a 59-year-old man (MA) with sizable recurrent tumors showing rapid progression. All three had failed standard of care chemoradiotherapy. DR had not tolerated Optune treatment and MA had failed Gliadel wafer and Avastin treatments. The patients received 2-hour OMT 1–4 times a day initially for 3 days in the clinic and subsequently at home. 5-min and 75-min post-contrast T1-weighted MRI scans were done periodically to assess the treatment response by obtaining differences in image intensities at the two time points.
Results: OMT was well tolerated by all three patients. They had no treatment-related serious adverse events. Their last MRI scans on Days 146, 42, and 179, respectively, showed substantial reductions in CET volume. The residual differences in image intensity in CET at 75 min indicated that there was marked shrinkage in both necrotic and active tumor tissues. T2-FLAIR MRI scans also showed attenuation of volume and intensity.
Conclusion : These findings demonstrate that in-home OMT alone has significant potential as a safe and effective noninvasive treatment for GBM through a novel and unique mechanism of action and is a new and powerful treatment option for end stage patients.
